Sounds like you have been eating a lot of sour grapes. Hope your opinion does not give you indigestion. CEO's jobs are not to play politics but to invest in the future of the company and make stockholders money.
Inversion has nothing to do with moving anyone to Ireland. If outsourcing some support services is cost effective, more power to them.
Your medicare premiums could possible increase due to the forced capital gains due to inversion. You also may have to pay an 3.8% increase on your tax rate in the year of capital gain if you hit the threshold due to Obama Care on high wage earners, not to mention loss of expense deductions and exemptions.
I do not know too many people still carrying forward losses in the last couple of years. Even my dogs are running a good race.
You are exactly correct. If you have been a long time share holder in Abbott and have a low cost basis in
Abbvie your tax bill ( Including capital gains on the high end 20%; 3.8% Obama Care Premium, plus your state and local taxes) could be as much as 30% of the value of your Abbvie Shares less your cost basis. The only way I can afford to pay this tax liability is to sell 1/3 of my Abbvie Shares and lose forever the dividend on those sold shares. This same tax event has happened to Medtronic in their inversion. This wipes out a lot of the advantage of the Abbvie split for the original Abbot long term shareholders. No effect if your shares are in an IRA or 401K.
Dividends will be taxed based on what country you live in not where company is tax domiciled. Just like any other foreign company.
Jak, sell your shares while you can still make a profit and invest in something that can make you a better return. This is not rocket science. With all your in-depth knowledge I would have thought you would have sold when it was still in the $52.00 range and moved on.
Announced a 5% increase with the May Dividend payment. Same active dates for previous dividend increases when it was under Abbott.
What Miles does with his personal money is his business. If Abbott bought the Deerpath Inn as a business investment than it becomes the business of the stockholders and the Board of Directors.
Go peddle your BS some where else. This is an Abbott investment board. If you think you are being taken advantage of, get out of the market.
The market finally woke up and realized that ABBV is not going to be first to market with a new Hep C drug, and at best they will only have a cocktail drug and the only way they are going to be able to compete with Gilead is by price.
Abbott has not been the parent for ABBV for the last year. I am certain that you may have meant past parent company. The companies separated into two different publicly traded companies on Jan. 1, 2013 and are independent of each other.
One of the poorest presentations that I have witnessed by both Miles White and Tom Freyman and the written comments to 4th quarter and total year results were even worse. Danced around many operational issues and had no good reason as to why they were bringing into the US $2 Billion (all of the 2014 Cash Flow from foreign operations) and paying US taxes on these funds. It looks on the surface that the reason is to buy back $2Billion (50million shares or 3%) of stock in order to help make 2014 EPS since Freyman made the statement in the conference that no good prospects for M&A activity on the horizon. If these two want any bonus dollars in 2014 than they need to get their act together. Looks like the analysts came away with the same take as I have.
Abt missed sales because: 1.) Diabetic sales neg. growth. 2.) Established Pharm Sales in mature markets (ie. Europe) show no growth. 3.) Pediatric sales in China, Vietnam and Saudi Arabia, have negatively been impacted in the 3rd and 4th Quarters. First and Second Qtr 2014 EPS are very low, and it looks like Abbott is bring into US 2014 foreign earnings and paying US taxes to buy back 3% of Abbott outstanding share in order to make 2014 EPS targets.